menu
    • menu
    [{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Vocimagene Amiretrorepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Biosciences \/ Denovo Biopharma"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Tocagen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Tocagen"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Biosciences \/ Alger"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"FB-102","moa":"CD122","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ TD Cowen"}]

    Find Clinical Drug Pipeline Developments & Deals by Forte Biosciences

    Menu

    Forte Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-102

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Forte Biosciences Announces Pricing of $75 Million Public Offering

                            Details : The proceeds from the offering will be used to fund the clinical development of FB-102, which is being evaluated for the treatment of celiac disease.

                            Product Name : FB-102

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 25, 2025

                            Lead Product(s) : FB-102

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-102

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : OrbiMed Advisors

                            Deal Size : $53.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Forte Biosciences Raises $53M to Advance FB102 in Autoimmune Disorders

                            Details : The proceeds will support the clinical advancement of FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

                            Product Name : FB-102

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 20, 2024

                            Lead Product(s) : FB-102

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : OrbiMed Advisors

                            Deal Size : $53.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-102

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Alger

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

                            Details : The net financing will support the advancement of FB-102, which targets CD-122 and has demonstrated potentially best in class activity in graft versus host disease (GvHD).

                            Product Name : FB-102

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2023

                            Lead Product(s) : FB-102

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Alger

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

                            Details : Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measu...

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            February 09, 2021

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forte Biosciences Shares Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statist...

                            Details : The primary endpoint of EASI-50 was achieved by 58% of subjects on FB-401 compared to 60% of subjects on placebo. Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 en...

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            February 09, 2021

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of At...

                            Details : FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and ...

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forte Biosciences Dosed First Patient in the Clinical Trial of FB-401 for the Treatment of Children and Adults...

                            Details : The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis (AD).

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            September 29, 2020

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forte Biosciences, Inc. Announces Issuance of New U.S. Patent

                            Details : Forte Biosciences announced the issuance of its seventh U.S. patent (10,682,379), broadening protection to include methods for culturing gram negative bacteria from the skin.

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 18, 2020

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vocimagene Amiretrorepvec

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets

                            Details : The acquisition includes Tocagen's retroviral replicating vector platform, investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC and several other development programs.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : Vocimagene Amiretrorepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Forte Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Tocagen

                            Deal Size : $25.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Tocagen and Forte Biosciences Announce Merger

                            Details : The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.

                            Product Name : FB-401

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            February 19, 2020

                            Lead Product(s) : FB-401

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Tocagen

                            Deal Size : $25.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth